125 related articles for article (PubMed ID: 2478002)
1. [Effect of estrogen treatment on antithrombin III activity in patients with carcinoma of the prostate].
Hayashi T; Takenawa J; Ryoji O; Hiura M; Taki Y; Kiriyama T
Hinyokika Kiyo; 1989 May; 35(5):807-13. PubMed ID: 2478002
[TBL] [Abstract][Full Text] [Related]
2. [Hormonal environment following treatment with a small dose of estrogen--small dose of estrogen alone and in combination with an anti-androgen].
Hayashi T; Taki Y; Ikai K; Hiura M; Kiriyama T
Hinyokika Kiyo; 1987 Jul; 33(7):1035-42. PubMed ID: 2446483
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
Akaza H; Usami M; Kotake T; Koiso K; Aso Y
Jpn J Clin Oncol; 1993 Jun; 23(3):178-85. PubMed ID: 7688829
[TBL] [Abstract][Full Text] [Related]
5. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
Ehara H; Katoh S; Nakane K; Katoh T; Takada T; Kojima K; Kamei S; Hagiwara N; Yuhara K; Takahashi Y; Fujimoto Y; Fujihiro S; Kanimoto Y; Deguchi T
Hinyokika Kiyo; 2009 Apr; 55(4):199-203. PubMed ID: 19462824
[TBL] [Abstract][Full Text] [Related]
6. The choice of estrogen preparations in the treatment of prostatic cancer.
Morales A; Pujari B
Can Med Assoc J; 1975 Nov; 113(9):865-7. PubMed ID: 1182631
[TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation of CMA in the treatment of prostatic cancer].
Fukuoka H; Goto A; Murai T; Satomi Y; Moriyama M; Senga Y; Shirai K; Nakao H
Hinyokika Kiyo; 1986 Dec; 32(12):1821-30. PubMed ID: 2435131
[TBL] [Abstract][Full Text] [Related]
8. [Hormone therapy in carcinoma of the prostate].
Marberger H
Wien Klin Wochenschr; 1966 Jul; 78(29):512-4 passim. PubMed ID: 5992834
[No Abstract] [Full Text] [Related]
9. Cholesterol ester metabolism in plasma during estrogen and antiandrogen treatment in men with carcinoma of the prostate.
Wallentin L; Varenhorst E
J Lab Clin Med; 1981 Dec; 98(6):906-16. PubMed ID: 6458644
[TBL] [Abstract][Full Text] [Related]
10. [Antithrombin III levels in patients with advanced carcinoma of the prostate treated with estrogens].
Montserrat Orri V; de Torres Mateos JA; Malet Carreras JM; Idoipe Tomás JI; Morote Robles J
Actas Urol Esp; 1985; 9(4):327-30. PubMed ID: 4050560
[No Abstract] [Full Text] [Related]
11. [Clinical studies on endocrine therapy of prostatic carcinoma (2): Prognosis of patients with prostatic carcinoma given endocrine therapy, and analyses of causes of death and side effects of endocrine therapy].
Kumamoto Y; Tsukamoto T; Umehara T; Shimazaki J; Fuse H; Oshima H; Takeuchi H; Yoshida O; Okada K; Saito Y
Hinyokika Kiyo; 1990 Mar; 36(3):285-93. PubMed ID: 2191570
[TBL] [Abstract][Full Text] [Related]
12. [Progress of endocrine therapy for prostate cancer and results].
Kanetake H
Gan To Kagaku Ryoho; 1996 Mar; 23(4):413-7. PubMed ID: 8678491
[TBL] [Abstract][Full Text] [Related]
13. Effect of hormonal manipulation on antithrombin III activity in patients with prostatic carcinoma.
Henny CP; ten Cate H; Dabhoiwala NF; Büller HR; ten Cate JW
Eur Urol; 1984; 10(3):202-6. PubMed ID: 6233149
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.
Pomerantz M; Manola J; Taplin ME; Bubley G; Inman M; Lowell J; Beard C; Kantoff PW; Oh WK
J Urol; 2007 Jun; 177(6):2146-50. PubMed ID: 17509304
[TBL] [Abstract][Full Text] [Related]
15. [Effects of oestrogens on cardiovascular risk factors in patients with carcinoma of the prostate (author's transl)].
Varenhorst E; Carlström K; Karlberg BE; Risberg B; Wallentin L; Wranne B
Urologe A; 1982 Jan; 21(1):34-8. PubMed ID: 6805122
[TBL] [Abstract][Full Text] [Related]
16. Effect of estrogen therapy on metastatic carcinoma of the prostate.
Anikwe RM
Int Surg; 1977 Oct; 62(10):532-6. PubMed ID: 591215
[TBL] [Abstract][Full Text] [Related]
17. Hormone therapy in women in the menopause transition. Randomised, double-blind, placebo-controlled trial of effects on body weight, blood pressure, lipoprotein levels, antithrombin III activity, and the endometrium.
Khoo SK; Coglan MJ; Wright GR; DeVoss KN; Battistutta D
Med J Aust; 1998 Mar; 168(5):216-20. PubMed ID: 9539899
[TBL] [Abstract][Full Text] [Related]
18. Cancer of the prostate:estrogen therapy: natural conjugated estrogen vs. Stillbestrol: A point of view.
Kaplan L
Rev Surg; 1968; 25(5):323-9. PubMed ID: 4301296
[No Abstract] [Full Text] [Related]
19. [Inhibition of the free, biologically active testosterone level by Turisteron in patients with prostate cancer].
Stahl F; Schnorr D; Rohde W; Dörner G
Z Urol Nephrol; 1987 Mar; 80(3):135-8. PubMed ID: 3604472
[TBL] [Abstract][Full Text] [Related]
20. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
